Glucose Transporter Type 1 Deficiency Syndrome - 13 Studies Found
Active, not recruiting |
: Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) : Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) : 2013-10-31 :
|
Recruiting |
: An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome : Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS) : 2014-01-13 : Drug: Triheptanoin Schedule A: Subjects previously treated |
Recruiting |
: Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) : Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) : 2016-11-07 :
|
Enrolling by invitation |
: Study to Assess the Long Term Safety and Efficacy of UX007 in Subjects With Glucose Type 1 DS : Glucose Transporter Type 1 Deficiency Syndrome : 2015-11-03 : Drug: UX007 UX007 is a liquid intended for oral (PO) administration. |
Recruiting |
: Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS : Glut1 Deficiency Syndrome : 2013-12-03 : Drug: GLUT1 DS |
Active, not recruiting |
: Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome : Glucose Transporter Type 1 Deficiency Syndrome : 2013-11-27 : Drug: Triheptanoin Triheptanoin (C7 oil) is a triglyceride of the anaplerotic odd-chain fatty acid hepto |
Not yet recruiting |
: Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D) :
|
Completed |
: Evaluation of Keyo in Children With Epilepsy :
|